Published on October 20, 2009 at 1:52 AM
Bio-Bridge Science, Inc. (OTCBB:BGES), a biotechnology company engaged in the commercial development of vaccines and vaccine-related products announced today that the Company received a business license from the Beijing Administration for Industry and Commerce of the People’s Republic of China (“PRC”) indicating approval of the formation of Bio-Bridge JRS Biosciences (Beijing) Co., Ltd. (“Bio-Bridge JRS”). Bio-Bridge JRS, is located in Beijing, China, and is expected to commercially produce cell culture medium and related biomaterials for use in scientific research and vaccine production. Bio-Bridge JRS will complement Bio-Bridge Science’s previous acquisition of Xinheng Baide Biotechnology Co., Ltd., a serum manufacturing company, by strengthening the Company’s position as a vaccine-related biomaterials supplier in the PRC.
“We are pleased to receive the business license indicating approval of the formation of Bio-Bridge JRS by the Beijing City government of the PRC,” said Dr. Liang Qiao, Chairman and CEO of Bio-Bridge Science. “We expect Bio-Bridge JRS to provide Bio-Bridge Science with an additional source of revenue, diversified product offerings, as well as, cell culture medium and bio-materials for use in our internal vaccine development.”
SOURCE Bio-Bridge Science, Inc.